T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Supernus Pharmaceuticals
SUPN
$2.74B
| $995K | ﹤0.01% |
48,860
+4,850
| +11% | +$86K |
|
|
ENZY
1702
DELISTED
Enzymotec Ltd
ENZY
| $986K | ﹤0.01% |
304,445
| – | – |
|
|
PACW
1703
DELISTED
PacWest Bancorp
PACW
| $985K | ﹤0.01% |
24,749
-8,080
| -25% | -$317K |
|
|
AXON
1704
Axon Enterprise
AXON
$50B
| $983K | ﹤0.01% |
39,513
-554,937
| -93% | -$11.5M |
|
|
UNT
1705
DELISTED
UNIT Corporation
UNT
| $982K | ﹤0.01% |
63,100
-46,800
| -43% | -$620K |
|
1706
Manitowoc
MTW
$753M
| $977K | ﹤0.01% |
44,802
+4,526
| +11% | +$98.4K |
|
1707
AMN Healthcare
AMN
$1.34B
| $970K | ﹤0.01% |
24,277
| – | – |
|
1708
Dolby
DLB
$5.84B
| $964K | ﹤0.01% |
20,149
+11
| +0.1% | +$502 |
|
1709
Chemours
CC
$2.3B
| $959K | ﹤0.01% |
116,429
+18,532
| +19% | +$165K |
|
|
WAGE
1710
DELISTED
WageWorks, Inc.
WAGE
| $958K | ﹤0.01% |
16,014
-63,074
| -80% | -$3.49M |
|
1711
Renasant Corp
RNST
$4B
| $956K | ﹤0.01% |
29,567
+6,930
| +31% | +$231K |
|
|
CTB
1712
DELISTED
Cooper Tire & Rubber Co.
CTB
| $951K | ﹤0.01% |
31,880
| – | – |
|
|
ESPR
1713
DELISTED
Esperion Therapeutics
ESPR
| $949K | ﹤0.01% |
96,040
-545
| -0.6% | -$9.03K |
|
|
ODP
1714
DELISTED
ODP
ODP
| $949K | ﹤0.01% |
28,674
+7,800
| +37% | +$381K |
|
|
PDM
1715
Piedmont Realty Trust
PDM
$1.2B
| $949K | ﹤0.01% |
44,057
+1,287
| +3% | +$26.1K |
|
|
CXP
1716
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
| $945K | ﹤0.01% |
44,163
+9,900
| +29% | +$214K |
|
1717
Interactive Brokers
IBKR
$41.4B
| $942K | ﹤0.01% |
106,468
-16,400
| -13% | -$156K |
|
1718
Viavi Solutions
VIAV
$10.6B
| $940K | ﹤0.01% |
141,823
+185
| +0.1% | +$1.23K |
|
|
MNR
1719
DELISTED
Monmouth Real Estate Investment Corp
MNR
| $937K | ﹤0.01% |
70,682
| – | – |
|
1720
Primerica
PRI
$9.62B
| $935K | ﹤0.01% |
16,330
| – | – |
|
|
CNSL
1721
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $935K | ﹤0.01% |
34,322
| – | – |
|
|
FMER
1722
DELISTED
FIRSTMERIT CORP
FMER
| $934K | ﹤0.01% |
46,092
+86
| +0.2% | +$1.87K |
|
1723
Trustmark
TRMK
$2.8B
| $930K | ﹤0.01% |
37,429
-5,800
| -13% | -$140K |
|
|
TIME
1724
DELISTED
Time Inc.
TIME
| $927K | ﹤0.01% |
56,339
+12,000
| +27% | +$186K |
|
1725
Terex
TEX
$7.57B
| $921K | ﹤0.01% |
45,336
-7,600
| -14% | -$174K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.